Annals of Clinical and Experimental Neurology最新文献

筛选
英文 中文
Single-Stage Extracranial and Intracranial Stenting of the Internal Carotid Artery in a Patient with Open Circle of Willis and Associated Renovascular Hypertension 一期颅内外支架植入术治疗开放性威利斯环伴肾血管性高血压患者
Annals of Clinical and Experimental Neurology Pub Date : 2023-06-21 DOI: 10.54101/acen.2023.2.11
M. Agarkov, A. Safuanov, S.T. Evreeva, O.B. Gertsog, O.S. Safuanova, Vitaly V. Popov, A. Khilchuk
{"title":"Single-Stage Extracranial and Intracranial Stenting of the Internal Carotid Artery in a Patient with Open Circle of Willis and Associated Renovascular Hypertension","authors":"M. Agarkov, A. Safuanov, S.T. Evreeva, O.B. Gertsog, O.S. Safuanova, Vitaly V. Popov, A. Khilchuk","doi":"10.54101/acen.2023.2.11","DOIUrl":"https://doi.org/10.54101/acen.2023.2.11","url":null,"abstract":"We describe a case of 72-year-old patient with recurrent transient ischemic attacks in the right internal carotid artery (ICA) territory associated with uncontrolled hypertension. Duplex ultrasonography und carotid angiography showed a 60% stenosis with signs of a vulnerable plaque in the cervical segment, as well as a 90% stenosis in the cavernous segment of the right ICA. After further examination the patient was diagnosed with an 80% renal artery stenosis. First, the patient had a single-stage stenting for extracranial and intracranial stenoses of the right ICA, then left renal artery stenting. No intraoperative and postoperative complications were observed. These results show that this surgical treatment is minimally invasive, safe, and effective in symptomatic patients and may be considered for the disease.","PeriodicalId":36946,"journal":{"name":"Annals of Clinical and Experimental Neurology","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86284007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
State-of-the-Art Technologies for Studying Cellular and Molecular Mechanisms Underlying Alzheimer's Disease 研究阿尔茨海默病的细胞和分子机制的最新技术
Annals of Clinical and Experimental Neurology Pub Date : 2023-06-21 DOI: 10.54101/acen.2023.2.10
M. Mukhamedyarov, Liaisan A. Akhmadieva, K. K. Nagiev, A. Zefirov
{"title":"State-of-the-Art Technologies for Studying Cellular and Molecular Mechanisms Underlying Alzheimer's Disease","authors":"M. Mukhamedyarov, Liaisan A. Akhmadieva, K. K. Nagiev, A. Zefirov","doi":"10.54101/acen.2023.2.10","DOIUrl":"https://doi.org/10.54101/acen.2023.2.10","url":null,"abstract":"Alzheimer's disease (AD) is the most common neurodegenerative disease and cause of dementia. It is associated with progressive cognitive decline due to the development of cortical and hippocampal atrophy. \u0000We reviewed key factors in AD pathogenesis, such as synaptic dysfunction, accumulation and aggregation of amyloid beta (A) peptide, tau phosphorylation causing neurofibrillary tangles, mitochondrial dysfunction, and neuroinflammation. We studied the dysbiosis role in AD development and demonstrated how much the bidirectional communication between the gut and brain sheds new light on some pathogenic processes underlying AD. We reviewed state-of-the-art biomedical technologies for studying AD: transgenic models, electrophysiological techniques, optogenetics, multi-omics approaches, neuroimaging, etc. New biomedical technologies significantly expanded our current knowledge of the AD pathogenesis and laid the groundwork for state-of-the-art treatment approaches.","PeriodicalId":36946,"journal":{"name":"Annals of Clinical and Experimental Neurology","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85496057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Several Risk Factors for Aneurysmal Subarachnoid Hemorrhage 动脉瘤性蛛网膜下腔出血的几个危险因素
Annals of Clinical and Experimental Neurology Pub Date : 2023-06-21 DOI: 10.54101/acen.2023.2.8
P. Shnyakin, I. A. Kazadaeva
{"title":"Several Risk Factors for Aneurysmal Subarachnoid Hemorrhage","authors":"P. Shnyakin, I. A. Kazadaeva","doi":"10.54101/acen.2023.2.8","DOIUrl":"https://doi.org/10.54101/acen.2023.2.8","url":null,"abstract":"We reviewed current literature on the role of seasonal, meteorological, or circadian factors in ruptured cerebral aneurysms. We found that cerebral aneurysm rupture most frequently occurs in winter and spring, and less frequently in summer. The highest number of ruptured cerebral aneurysms happens in the morning, between 8 am and 12 pm. The data regarding meteorological factors' effect on the risk of cerebral aneurysm rupture are conflicting. However, it should be noted that changes in barometric pressure and falling temperature are associated with the risk of aneurysmal subarachnoid hemorrhage.","PeriodicalId":36946,"journal":{"name":"Annals of Clinical and Experimental Neurology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77073355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
B Cell Depletion Therapy as a Cutting-Edge Treatment of Demyelinating Diseases of the Central Nervous System B细胞耗竭疗法作为中枢神经系统脱髓鞘疾病的前沿治疗方法
Annals of Clinical and Experimental Neurology Pub Date : 2023-06-21 DOI: 10.54101/acen.2023.2.9
T. Simaniv, A. Belkina, M. Zakharova
{"title":"B Cell Depletion Therapy as a Cutting-Edge Treatment of Demyelinating Diseases of the Central Nervous System","authors":"T. Simaniv, A. Belkina, M. Zakharova","doi":"10.54101/acen.2023.2.9","DOIUrl":"https://doi.org/10.54101/acen.2023.2.9","url":null,"abstract":"Demyelinating diseases of the central nervous system and multiple sclerosis in particular are a pressing issue for medical community and society as a whole. Deve- lopment and implementation of highly effective specific therapy significantly slow the disease progression and help maintain patients' quality of life and social participation. We analyzed pathogenic mechanisms of multiple sclerosis and other B cell-mediated diseases and reviewed therapeutic options for main disease stages.","PeriodicalId":36946,"journal":{"name":"Annals of Clinical and Experimental Neurology","volume":"412 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74008673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody 降钙素基因相关肽单克隆抗体治疗高频发作性和慢性偏头痛
Annals of Clinical and Experimental Neurology Pub Date : 2023-06-21 DOI: 10.54101/acen.2023.2.3
L. Dobrynina, M. A. Afanasev, A. Belopasova, M. Gubanova, E. V. Baydina
{"title":"The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody","authors":"L. Dobrynina, M. A. Afanasev, A. Belopasova, M. Gubanova, E. V. Baydina","doi":"10.54101/acen.2023.2.3","DOIUrl":"https://doi.org/10.54101/acen.2023.2.3","url":null,"abstract":"Introduction. High prevalence of migraine and its impact on quality of life requires the development of original agents. In 2020, fremanezumab, a new calcitonin gene-related peptide monoclonal antibody was authorized in Russia. \u0000Objective: to evaluate safety and effectiveness of fremanezumab in patients with high-frequency episodic migraine (HF EM) and chronic migraine (CM). \u0000Materials and methods. We assessed 60 patients at the age of 35.5 8.96 years (85%, females) with HFEM and CM with and without aura who were either receiving preventive treatment or not. Fremanezumab was administered subcutaneously at a single dose of 675 mg. The study participants were followed-up for efficacy in 3 months. The investigators assessed change in the number of days with headache per month as well as headache intensity, its impact on the daily activities, anxiety, and depression. \u0000Results. By the end of month 3 post dosing, the number of days with headache decreased by 50% in 76.7% of participants where 77.8% of individuals suffered from HF EM and 72.7% of individuals had CM while headache intensity decreased in all the patients equally. No response (decrease in the number of days with headache by 30%) was reported in 15% of participants including 14.8% of individuals with HF EM and 15.2% of individuals with CM. By the end of study month 3, 81% of participants demonstrated no anxiety symptoms and 79% of participants showed no depression with significant MIDAS and HIT-6 score decline in both groups. Only 3 (5%) patients noted adverse events (redness, itching at the administration site). \u0000Conclusion. We documented higher fremanezumab safety and effectiveness in patients with EM and CM in real-world practice as compared to fremanezumab safety and efficacy in randomized clinical trials. A single dose of fremanezumab (675 mg) resulted in effective migraine prevention, decline in comorbid anxiety and depression, and improved quality of life during 3-month follow-up.","PeriodicalId":36946,"journal":{"name":"Annals of Clinical and Experimental Neurology","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85283280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examining the frequency of dysphagia and the predictive factors of dysphagia that require attention in patients with Parkinson's disease 检查帕金森病患者吞咽困难的频率和需要注意的吞咽困难的预测因素
Annals of Clinical and Experimental Neurology Pub Date : 2023-03-29 DOI: 10.54101/acen.2023.1.2
Tahereh Babajani Roshan, C. Behzad, P. Saadat, Ali Bijani, M. Dehghan, Alijan Ahmadi Ahangar
{"title":"Examining the frequency of dysphagia and the predictive factors of dysphagia that require attention in patients with Parkinson's disease","authors":"Tahereh Babajani Roshan, C. Behzad, P. Saadat, Ali Bijani, M. Dehghan, Alijan Ahmadi Ahangar","doi":"10.54101/acen.2023.1.2","DOIUrl":"https://doi.org/10.54101/acen.2023.1.2","url":null,"abstract":"Introduction. Due to the prevalence of dysphagia in patients with Parkinson's disease (PD) and its complications such as aspiration pneumonia, which is the main cause of death in these patients, PD-related disability can be prevented by early diagnosis and treatment of dysphagia. \u0000Objective. The present study was aimed at investigating the frequency of dysphagia in PD patients. \u0000Materials and methods. This cross-sectional study included 150 PD patients visiting a Neurology Clinic. The severity of PD was determined based on the Unified Parkinson Disease Rating Scale (UPDRS) and modified Hoen and Yahr (HYS) Scale. The Munich Dysphagia Test-Parkinson's disease (MDT-PD) questionnaire was used to assess dysphagia. Comparisons were made using generalized Fisher exact, Chi-square, ANOVA, and KruskalWallis tests. Predictive factors were analyzed using logistic regression. Statistical analyses were performed at significance level of 0.05. \u0000Results. Out of all 150 patients referred to the Clinic, the prevalence of dysphagia requiring attention was 25.3% (n = 38). The patients of the three groups according to the MDT-PD (no noticeable dysphagia, noticeable oropharyngeal, and dysphagia with aspiration risk) had a significant difference only in terms of the PD duration (p 0.001). In the predicting of dysphagia, the longer PD duration (p = 0.011) and homemaker occupation (p = 0.033) were protective factors, while female gender was a risk factor (p = 0.011). \u0000Conclusion. The prevalence of dysphagia requiring attention in the studied patients was 25.3%. It decreased with the longer duration of the disease, and its prevalence was lower in homemaker patients, while the odds of dysphagia was 5.8 times higher in women than in men.","PeriodicalId":36946,"journal":{"name":"Annals of Clinical and Experimental Neurology","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87543786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-Covid disorders of nervous system: personal experience covid后神经系统疾病:个人经历
Annals of Clinical and Experimental Neurology Pub Date : 2023-03-29 DOI: 10.54101/acen.2023.1.10
Larisa A. Shchepankevitch, I.E. Arkhipov, V. V. Polyanskaya, I.A. Veretelnikov, Elena V. Taneeva, Ksenya V. Rerikh
{"title":"Post-Covid disorders of nervous system: personal experience","authors":"Larisa A. Shchepankevitch, I.E. Arkhipov, V. V. Polyanskaya, I.A. Veretelnikov, Elena V. Taneeva, Ksenya V. Rerikh","doi":"10.54101/acen.2023.1.10","DOIUrl":"https://doi.org/10.54101/acen.2023.1.10","url":null,"abstract":"Introduction. In the COVID-19 pandemic, high lethality as well as long-term outcomes are getting more and more relevant. According to the accumulated study results, COVID-19 affects the nervous system both directly and indirectly. \u0000Objective: to study the variants of post-COVID syndrome based on the data from the State Novosibirsk Regional Clinical Hospital from July 2020 to February 2022. \u0000Materials and methods. We have performed post hoc analysis of the medical records of 1,500 patients with a past history of COVID-19 admitted following various neurological disorders manifested from July 2020 to February 2022. \u0000Results. While temporary and pathogenetic association with past COVID-19 was revealed in 455 patients, primary involvement of the central nervous system was reported in 91.6% of cases, primary involvement of the peripheral nervous system in 8.1% of cases, and musculoskeletal disorder (idiopathic myodystrophy) in 0.3% of cases. \u0000Conclusion. Prevalence of the neurological variants of post-COVID syndrome is still unknown. However, patients with severe COVID-19 are more susceptible to neurological complications during the following six months.","PeriodicalId":36946,"journal":{"name":"Annals of Clinical and Experimental Neurology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77022065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuroinflammation as secondary damage in head injury 神经炎症是颅脑损伤的继发性损伤
Annals of Clinical and Experimental Neurology Pub Date : 2023-03-29 DOI: 10.54101/acen.2023.1.7
A. Karchevskaya, O. Payushina, E. Sharova, L. Oknina, O. Titov
{"title":"Neuroinflammation as secondary damage in head injury","authors":"A. Karchevskaya, O. Payushina, E. Sharova, L. Oknina, O. Titov","doi":"10.54101/acen.2023.1.7","DOIUrl":"https://doi.org/10.54101/acen.2023.1.7","url":null,"abstract":"Head injury is one of the main disability causes among the working-age population. Stroke energy induces mechanical injury of tissues to launch secondary damage, i.e. neurotransmission, blood-brain barrier disruption, blood infiltration of brain tissues, cytokine and chemokine overexpression, and other processes. Activated by the injury, microglia plays a special part to initially 'protect' intact tissues from the products of necrosis and apoptosis. After the injury, microglia rapidly differentiates to phenotypes М1 and М2. Pro-inflammatory phenotype М1 produces neuronal cytotoxic cytokines including tumor necrosis factor-, interleukins (IL)-6 and IL-1, and NO that induce apoptosis while phenotype М2 secretes IL-4 and IL-13 that may supposedly reduce inflammation and improve recovery of brain tissues. М2 response lasts much less than М1 response, and increasing pro-inflammatory activation leads to further neuronal death, which affects cognitive and physical status of patients with head injury. The review covers main biochemical processes in the injured brain and possible ways of neuroinflammation modulation.","PeriodicalId":36946,"journal":{"name":"Annals of Clinical and Experimental Neurology","volume":"517 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77148375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors that pre-determine the main subtypes of ischemic stroke in middle-aged and senior women 预测中老年妇女缺血性脑卒中主要亚型的因素
Annals of Clinical and Experimental Neurology Pub Date : 2023-03-29 DOI: 10.54101/acen.2023.1.1
M. Maximova, V. Y. Sazonova
{"title":"Factors that pre-determine the main subtypes of ischemic stroke in middle-aged and senior women","authors":"M. Maximova, V. Y. Sazonova","doi":"10.54101/acen.2023.1.1","DOIUrl":"https://doi.org/10.54101/acen.2023.1.1","url":null,"abstract":"Introduction. Brain health and active longevity are affected by a number of stroke risk factors. We should identify their relative impact on the main subtypes of ischemic stroke (IS) in middle-aged and senior women to consider prevention and management strategies. \u0000Objective. To assess prevalence of isolated and combined factors that may contribute with a high probability to development of the various IS subtypes in women aged 4574 years. \u0000Materials and methods. The study included 348 female patients aged 4574 years including 145 inpatients with carotid IS (main group) from Neurology Department 2, the Research Center of Neurology, and 203 women with cognitive disorders due to the chronic cerebral ischemia (controls). To assess the impact of various risk factors on the main IS subtypes, we generated multivariate predictive models using logistic regression and the Wald test. \u0000Results. Predictive modeling of atherothrombotic IS demonstrated that type 2 diabetes mellitus increases IS risk by over 5 times (odds ratio [OR] = 5.961; 95% confidence interval [CI] 1.10232.257; р = 0.038); internal carotid artery stenosis, by 7 times (OR = 7.187; 95% CI 1.82728.273; р = 0.005); history of transient ischemic attacks (TIA), by 61 times (OR = 61.442; 95% CI 7.673491.998; р 0.001); excessive alcohol intake, by 49 times (OR = 49,382; 95% CI 4.557535.121; р = 0.001); and HTN severity, by 4 times (OR = 4.445; 95% CI 2.3318.476; р 0.001). Predictive modeling of cardioembolic IS demonstrated that post-infarction cardiosclerosis increases IS risk by over 118 times (OR = 118.025; 95% CI 5.2102673.796; р = 0.003), atrial fibrillation, by 108 times (OR = 108.493; 95% CI 24.312484.159; р 0.001), history of TIA, by over 71 times (OR = 71.558; 95% CI 7.945644.535; р 0.001); and HTN severity, by over 3 times (OR = 3.957; 95% CI 2.0697.566; р 0.001). Predictive modeling of lacunar IS demonstrated that type 2 diabetes mellitus increases IS risk by 8 times (OR = 8.324; 95% CI 1.92336.041; р = 0.005), history of IS, by over 8 times (OR = 8.99; 95% CI 1.77245.598; р = 0.008); and HTN severity, by 7 times (OR = 7.139; 95% CI 3.49114.599; р 0.001). \u0000Conclusion. We identified a number of risk factors that may contribute to the development of the main IS subtypes in middle-aged and senior women.","PeriodicalId":36946,"journal":{"name":"Annals of Clinical and Experimental Neurology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82045999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cerebrovascular complications of hematopoetic stem cell transplantation in patients with hematologic malignancies 恶性血液病患者造血干细胞移植的脑血管并发症
Annals of Clinical and Experimental Neurology Pub Date : 2023-03-29 DOI: 10.54101/acen.2023.1.4
A. Polushin, I. Skiba, E. Bakin, M. D. Vladovskaya, Victoria A. Yakovleva, I. Moiseev, S. Yanishevskiy, I. Voznyuk, A. Kulagin
{"title":"Cerebrovascular complications of hematopoetic stem cell transplantation in patients with hematologic malignancies","authors":"A. Polushin, I. Skiba, E. Bakin, M. D. Vladovskaya, Victoria A. Yakovleva, I. Moiseev, S. Yanishevskiy, I. Voznyuk, A. Kulagin","doi":"10.54101/acen.2023.1.4","DOIUrl":"https://doi.org/10.54101/acen.2023.1.4","url":null,"abstract":"Introduction. Modern transplantation and biological therapy methods are associated with a wide range of adverse events and complications. Incidence and variety of neurological complications mostly depend on myelo- and immunosuppression severity and duration as well as on donor's and recipient's characteristics. The most frequent complications involving the nervous system include neurotoxic reactions, infections, autoimmune and lymphoproliferative diseases, and dysmetabolic conditions as well as cerebrovascular complications that potentially affect transplantation outcomes. \u0000Objective. To evaluate the impact of post-transplantation cerebrovascular events (CVEs) on transplantation outcomes in patients with hematologic malignancies. \u0000Materials and methods. We analyzed 899 transplantations performed at the Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology, and Transplantation, Pavlov First Saint Petersburg State Medical University, from 2016 to 2018. We assessed transplantation parameters and donor's and recipient's characteristics by intergroup comparison, pseudo-randomization (propensity score matching), KaplanMeier survival analysis, and log-rank tests. \u0000Results. Post-transplantatively, CVEs developed in 2.6% (n = 23) of cases: 13 (1.4%) ischemic strokes and 11 (1.2%) hemorrhagic strokes or intracranial hemorrhages were diagnosed. CVEs developed on days 99.5 39.2 post hematopoetic stem cell transplantation (HSCT). There were more patients with non-malignant conditions in the CVE group as compared to the non-CVE group (21.7% vs 7.9%; p = 0.017). Patients with CVE had a significantly lower Karnofsky index (75.6 21.3 vs 85.2 14.9; p = 0.008). Statistically, we also note some non-significant trends: patients with CVE more often underwent allogenic HSCT (82.6% vs 64.0%; p = 0.077) while donors were more often partially (rather than totally) HLA compatible for recipients (39.1% vs 21.1%; p = 0.33). Patients with CVE more often had a history of venous thromboses (13.3% vs 4.2%; p = 0.077). Post-HSCT stroke decreased post-transplantation longevity by approximately 3 times (331.8 81.6 vs 897.9 25.4 post HSCT; p = 0.0001). In the CVE group, survival during first 180 days post HSCT (landmarks post-HSCT Day+60 and Day+180) was significantly lower as compared to that in the CVE-free group. If CVE developed during first 30 days and 100 days post HSCT, vascular catastrophe did not affect post-HSCT survival significantly. \u0000Conclusion. Whereas ischemic stroke is a long-term HSCT complication (beyond D+100 post transplantation), hemorrhagic stroke is a short-term complication (D0D+100 post HSCT). CVEs affect survival in patients with hematologic malignancies, especially those developed between D+60 and D+180 post HSCT. History of venous abnormalities, low Karnofsky index at HSCT initiation, and the type of allogenic HSCT, especially from half-matched donors, can be considered as negative outcome risk factors in post-HSCT CVE.","PeriodicalId":36946,"journal":{"name":"Annals of Clinical and Experimental Neurology","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82067958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信